Document Detail


Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody.
MedLine Citation:
PMID:  22401638     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of a humanized monoclonal antibody (mAb) having high affinity and specificity for cocaine in animal models are reviewed. The mAb reduced the concentration of cocaine in the brain of mice after intravenous injection of cocaine. In addition, the mAb increased the concentration of cocaine required to reinstate cocaine self-administration. These effects may predict clinical efficacy of a passive immunotherapy for reducing the probability of cocaine-induced relapse. However, in the presence of the mAb, once cocaine self-administration was reinstated, the consumption rate of cocaine was increased. This effect is hypothesized to result from a pharmacokinetic/pharmacodynamic interaction. A humanized mAb should minimize adverse events related to the immunogenicity of the mAb protein, and the specificity for cocaine should avoid adverse events related to interactions with physiologically relevant endogenous proteins.
Authors:
Andrew B Norman; William J Ball
Related Documents :
3522758 - Development of murine monoclonal antibodies to pneumocystis carinii.
22316488 - Purification of anti-japanese encephalitis virus monoclonal antibody by ceramic hydroxy...
10948998 - The major immediate-early genes of human cytomegalovirus induce two novel proteins with...
6107018 - Preparation of immune serum to immediate early and early polypeptides specified by herp...
3976168 - Immunochemical behaviour of a tumour-associated antigen obtained from an akr mouse lymp...
8787678 - Indirect recognition of donor hla-dr peptides in organ allograft rejection.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Immunotherapy     Volume:  4     ISSN:  1750-7448     ISO Abbreviation:  Immunotherapy     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-09     Completed Date:  2012-07-03     Revised Date:  2013-02-20    
Medline Journal Info:
Nlm Unique ID:  101485158     Medline TA:  Immunotherapy     Country:  England    
Other Details:
Languages:  eng     Pagination:  335-43     Citation Subset:  IM    
Affiliation:
Department of Pharmacology & Cell Biophysics and Department of Psychiatry & Behavioral Neuroscience, College of Medicine, University of Cincinnati, Cincinnati, OH 45237-0506, USA. andrew.norman@uc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anesthetics, Local* / adverse effects,  antagonists & inhibitors,  immunology,  pharmacokinetics
Animals
Antibodies, Monoclonal, Humanized* / adverse effects,  immunology,  pharmacokinetics,  therapeutic use
Brain / immunology,  metabolism
Cocaine* / adverse effects,  antagonists & inhibitors,  immunology,  pharmacokinetics
Cocaine-Related Disorders / immunology,  metabolism,  therapy*
Disease Models, Animal
Humans
Immunization, Passive*
Mice
Grant Support
ID/Acronym/Agency:
DP1 DA031386-02/DA/NIDA NIH HHS; DP1DA031386/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
0/Anesthetics, Local; 0/Antibodies, Monoclonal, Humanized; 50-36-2/Cocaine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Immunotherapy for acute kidney injury.
Next Document:  Catalytic peroxynitrite decomposition improves reperfusion injury after heart transplantation.